

Vitrolife announces changes to the executive management team after the acquisition of Igenomix

As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.

The executive management team will from 1 January, 2022, consist of:

Thomas Axelsson, President and Chief Executive Officer

Group Functions:

Francisco Jiménez, SVP Strategy & Corporate Development

Karin Koritz Russberg, SVP HR & Sustainability

Carlos Simón, Chief Scientific Officer

Patrik Tolf, Chief Financial Officer

Business Areas:

Claus Bisgaard, SVP Vitrolife Technology

Ricardo Capella, SVP Igenomix

Maria Forss, SVP Vitrolife Consumables

Business Functions:

Rickard Ericsson, SVP Vitrolife Sales & Marketing

Francisco Rodriguez, SVP Igenomix Affiliates

Gothenburg, December 1, 2021

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Contact persons:

Thomas Axelsson, CEO, tel: +46 31 721 80 01

Mikael Engblom, CFO, tel: +46 31 721 80 14

Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.